Literature DB >> 28342944

The anti-inflammatory mechanism of antidepressants - SSRIs, SNRIs.

Piotr Gałecki1, Joanna Mossakowska-Wójcik1, Monika Talarowska2.   

Abstract

The cytokine theory of depression no longer brings about any doubts. Experiments and research studies conducted in the last ten years have confirmed that both physical and psychological (emotional) stress increases the likelihood of occurrence of mental disorders (including depressive disorders) owing to the action of a series of hormonal and biochemical mechanisms. Selective serotonin reuptake inhibitors (SSRI) as well as serotonin and norepinephrine reuptake inhibitors (SNRIs) are some of the most commonly applied drugs in the world during pharmacotherapy of recurrent depressive disorder. The underestimated anti-inflammatory and anti-oxidative effect may be one of the potential mechanisms of action of the preparations mentioned above. The detailed specificity of action of this mechanism still remains unknown. The aim of our work will be to perform a review of contemporary literature in order to present the latest scientific reports regarding the anti-inflammatory effects of SSRIs and SNRIs. The mechanism of anti-inflammatory action may serve as a possible explanation for the efficacy of antidepressants from the groups of SSRIs and SNRIs.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28342944     DOI: 10.1016/j.pnpbp.2017.03.016

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  24 in total

Review 1.  Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience.

Authors:  M C Flux; Christopher A Lowry
Journal:  Neurobiol Dis       Date:  2019-08-24       Impact factor: 5.996

Review 2.  Major Depressive Disorder in Older Patients as an Inflammatory Disorder: Implications for the Pharmacological Management of Geriatric Depression.

Authors:  Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk
Journal:  Drugs Aging       Date:  2021-04-29       Impact factor: 3.923

3.  Brain Mitochondrial Dysfunction: A Possible Mechanism Links Early Life Anxiety to Alzheimer's Disease in Later Life.

Authors:  Qixue Wang; Mengna Lu; Xinyu Zhu; Xinyi Gu; Ting Zhang; Chenyi Xia; Li Yang; Ying Xu; Mingmei Zhou
Journal:  Aging Dis       Date:  2022-07-11       Impact factor: 9.968

Review 4.  Role of high mobility group box protein 1 in depression: A mechanistic and therapeutic perspective.

Authors:  Shu Wang; Yu-Guang Guan; Yan-Hua Zhu; Min-Zhong Wang
Journal:  World J Psychiatry       Date:  2022-06-19

5.  Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.

Authors:  Andrew J Melaragno
Journal:  Focus (Am Psychiatr Publ)       Date:  2021-06-17

6.  Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.

Authors:  Adrienne Grzenda; Prabha Siddarth; Kelsey T Laird; Jillian Yeargin; Helen Lavretsky
Journal:  Mol Psychiatry       Date:  2020-05-07       Impact factor: 15.992

Review 7.  Inflammation-driven brain and gut barrier dysfunction in stress and mood disorders.

Authors:  Ellen Doney; Alice Cadoret; Laurence Dion-Albert; Manon Lebel; Caroline Menard
Journal:  Eur J Neurosci       Date:  2021-05-17       Impact factor: 3.698

Review 8.  Mast Cell Activation in Brain Injury, Stress, and Post-traumatic Stress Disorder and Alzheimer's Disease Pathogenesis.

Authors:  Duraisamy Kempuraj; Govindhasamy P Selvakumar; Ramasamy Thangavel; Mohammad E Ahmed; Smita Zaheer; Sudhanshu P Raikwar; Shankar S Iyer; Sachin M Bhagavan; Swathi Beladakere-Ramaswamy; Asgar Zaheer
Journal:  Front Neurosci       Date:  2017-12-12       Impact factor: 4.677

Review 9.  Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations.

Authors:  Giovanni Ostuzzi; Davide Papola; Chiara Gastaldon; Georgios Schoretsanitis; Federico Bertolini; Francesco Amaddeo; Alessandro Cuomo; Robin Emsley; Andrea Fagiolini; Giuseppe Imperadore; Taishiro Kishimoto; Giulia Michencigh; Michela Nosé; Marianna Purgato; Serdar Dursun; Brendon Stubbs; David Taylor; Graham Thornicroft; Philip B Ward; Christoph Hiemke; Christoph U Correll; Corrado Barbui
Journal:  BMC Med       Date:  2020-07-15       Impact factor: 8.775

10.  Immunomodulation Eliminates Inflammation in the Hippocampus in Experimental Autoimmune Encephalomyelitis, but Does Not Ameliorate Anxiety-Like Behavior.

Authors:  Pece Kocovski; Nuzhat Tabassum-Sheikh; Stephanie Marinis; Phuc T Dang; Matthew W Hale; Jacqueline M Orian
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.